Warning Letter Record: Fareva Amboise (2026-04-10) — CGMP/Finished Pharmaceuticals/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
In short: **FDA Warning Letter — Fareva Amboise (April 10, 2026)** The FDA's Center for Veterinary Medicine issued a warning letter to Fareva Amboise (FEI 3000234005), France, following a September 2025 inspection, citing significant Current Good Manufacturing Practice (CGMP) violations under 21 CFR parts 210 and 211 for finished pharmaceutical manufacturing. The letter identifies failures in aseptic processing procedures, including inadequate airflow validation studies on the Grade A filling line (smoke studies did not demonstrate unidirectional airflow and revealed multiple deficiencies), incomplete dynamic airflow studies during filling operations, and poor aseptic technique by operators (improper handling of sterile components, inadequate disinfection procedures, and unsafe movements over critical surfaces). Fareva's December 2025 response acknowledging outdated equipment and environmental design deficiencies was deemed inadequate because it provided no specific timelines for implementing required corrections and omitted a risk assessment addressing the impact on sterile drug products.
Argus analysis
# FDA Warning Letter Analysis: Fareva Amboise
**Company and Findings**
Fareva Amboise, a pharmaceutical manufacturing facility in Pocé-sur-Cisse, France (FEI 3000234005), received a warning letter from the FDA's Center for Veterinary Medicine on April 10, 2026, following an inspection conducted September 8–16, 2025. The FDA determined that the facility's manufacturing methods, facilities, and controls do not conform to Current Good Manufacturing Practice (CGMP) regulations, rendering finished drug products adulterated under the Federal Food, Drug, and Cosmetic Act. The facility manufactures animal drug products for the U.S. market using aseptic processing.
**Regulatory Citations and Context**
The warning letter cites violations of 21 CFR parts 210 and 211, which establish mandatory CGMP standards for finished pharmaceuticals. Specific violations include 21 CFR 211.113(b), governing written procedures for preventing microbiological contamination in sterile drug products. The cited deficiencies span multiple critical areas: inadequate airflow visualization studies on Grade A aseptic filling lines showing non-unidirectional flow; poor aseptic technique including uncontrolled material handling and personnel positioning over sterile surfaces; insufficient media fill process simulations that fail to capture worst-case manufacturing conditions; and inadequate monitoring of personnel microbiological contamination in aseptic areas, including recovery of bacterial CFUs on operator forearms.
**Response Timeline and Industry Monitoring**
Fareva Amboise submitted responses on October 7, December 11, and December 23, 2025, and February 6, 2026. The FDA deemed all responses inadequate due to missing implementation timelines, insufficient risk assessments of contamination impacts, and failure to address systemic deficiencies comprehensively. Compliance officers in sterile manufacturing should monitor whether Fareva Amboise submits a revised corrective action plan with specific completion dates and closure evidence, and whether FDA issues a close-out letter confirming remediation or escalates enforcement action.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Fareva Amboise MARCS-CMS 723502 — April 10, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA Electronic Mail Product: Animal & Veterinary Drugs Recipient: Recipient Name Mr. David L. Rapy Recipient Title General Manager Fareva Amboise Zone Industrielle 29, route des industries 37530 Pocé-sur-Cisse France Issuing Office: Center for Veterinary Medicine United States Secondary Issuing Offices Center for Drug Evaluation and Research (CDER) United States April 10, 2026 CMS Case: 723502 WARNING LETTER Dear Mr. Rapy: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Fareva Amboise, FEI 3000234005, at Zone Industrielle 29, route des Industries 37 530 Pocé-sur-Cisse, France from September 8 to 16, 2025. This warning letter summarizes significant violations of FDA’s Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your October 7, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondences dated December 11, 2025, December 23, 2025, and February 6, 2026. During our inspection, our investigators observed specific violations including, but not limited to, the following. 1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)). Inadequate Smoke Studies Airflow visualization studies performed for your Grade A (b)(4) aseptic filling line, which is used to fill animal drug products for the U.S. market, did not demonstrate unidirectional air flow and revealed multiple deficiencies in airflow patterns and aseptic practices. For example: During (b)(4) installation, air flowed from the operator (positioned in the Grade B area while leaning into the barrier) toward the (b)(4) intervention site where uncovered (b)(4) on the (b)(4) were exposed. • Air flowed upward towards the Grade B area when (b)(4) was (b)(4) , leading to the (b)(4) and on top of (b)(4) , rather than maintaining unidirectional flow away from critical surfaces. • Laminar flow patterns during interventions performed around the filling area showed a tendency to stagnate and flow upward in the area between (b)(4) where operators make tubing connections. • Airflow was turbulent with an (b)(4) flow while stoppers were transferred from the stopper bowl to the stoppering machine and over the conveyor moving open bottle. Furthermore, y…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Fareva Amboise had FDA enforcement actions before?
- Yes. Argus HQ has recorded 2 total FDA actions tied to Fareva Amboise: 1 warning letter, 0 recalls, and 0 approval records.
- What FDA violations was Fareva Amboise cited for?
- The FDA Warning Letter to Fareva Amboise (issuing office: Center for Veterinary Medicine) cites: CGMP/Finished Pharmaceuticals/Adulterated. Classification: CGMP — Current Good Manufacturing Practice.
- When did FDA issue the warning letter to Fareva Amboise?
- FDA issued the letter (MARCS-CMS 723502) on 2026-04-10 and posted it publicly on fda.gov on 2026-07-21.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Warning Letter Record: Fareva Amboise (2026-04-10) — CGMP/Finished Pharmaceuticals/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-fareva-amboise-2026-04-10-cgmp
"Warning Letter Record: Fareva Amboise (2026-04-10) — CGMP/Finished Pharmaceuticals/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-fareva-amboise-2026-04-10-cgmp.
Argus HQ Research. "Warning Letter Record: Fareva Amboise (2026-04-10) — CGMP/Finished Pharmaceuticals/Adulterated." Digital Empire Holdings LLC. Accessed July 22, 2026. https://argushq.ai/fda/warning-letter/fda-wl-fareva-amboise-2026-04-10-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_fareva_amboise_2026_04_10_cgmp_2026,
title = {Warning Letter Record: Fareva Amboise (2026-04-10) — CGMP/Finished Pharmaceuticals/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-fareva-amboise-2026-04-10-cgmp},
note = {Accessed: July 22, 2026}
}